A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease

American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases

(2017) Niels Vande Casteele et al.   GASTROENTEROLOGY

Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease

(2016) W. Moon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies

(2016) Casper Steenholdt et al.   INFLAMMATORY BOWEL DISEASES

Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease

(2016) Casper Steenholdt et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases

(2016) Caroline Meyer Olesen et al.   PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONICpost hocanalysis

(2015) J.-F. Colombel et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy

(2015) Andres J. Yarur et al.   Clinical Gastroenterology and Hepatology

Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease

(2015) Mehmet Coskun et al.   CLINICAL PHARMACOKINETICS

Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab

(2015) Casper Steenholdt et al.   DIGESTIVE DISEASES AND SCIENCES

Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial

(2014) Casper Steenholdt et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD

(2014) Madeline Therese Frederiksen et al.   INFLAMMATORY BOWEL DISEASES

Association Between 6-Thioguanine Nucleotides Levels and Clinical Remission in Inflammatory Disease

(2014) Amelie Carla Moreau et al.   INFLAMMATORY BOWEL DISEASES

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

(2013) Remo Panaccione et al.   GASTROENTEROLOGY

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

(2013) Casper Steenholdt et al.   GUT

Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohnʼs Disease

(2013) Casper Steenholdt et al.   THERAPEUTIC DRUG MONITORING

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

(2011) C. Steenholdt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease

(2010) O. Pozler et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Management of Crohn's Disease in Adults

(2009) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY